Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

First data on treatment of NPC1 with Trappsol^® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks

At 48 weeks of the sub-study, 7 of 9 patients¹ showed stabilization or improvement in CGI-S score

Read more at globenewswire.com